These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683 [TBL] [Abstract][Full Text] [Related]
4. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux. Li JR; Cheng CL; Yang CR; Ou YC; Wu MJ; Ko JL Toxicol Lett; 2013 Jul; 220(3):267-76. PubMed ID: 23651616 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223 [TBL] [Abstract][Full Text] [Related]
6. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma. Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217 [TBL] [Abstract][Full Text] [Related]
7. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154 [TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625 [TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145 [TBL] [Abstract][Full Text] [Related]
10. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292 [TBL] [Abstract][Full Text] [Related]
11. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
12. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782 [TBL] [Abstract][Full Text] [Related]
13. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560 [TBL] [Abstract][Full Text] [Related]
14. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613 [TBL] [Abstract][Full Text] [Related]
15. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma. Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769 [TBL] [Abstract][Full Text] [Related]
16. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Moon du G; Lee SE; Oh MM; Lee SC; Jeong SJ; Hong SK; Yoon CY; Byun SS; Park HS; Cheon J Int J Oncol; 2014 Sep; 45(3):1027-35. PubMed ID: 24969552 [TBL] [Abstract][Full Text] [Related]
17. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334 [TBL] [Abstract][Full Text] [Related]
18. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Gobin B; Battaglia S; Lanel R; Chesneau J; Amiaud J; Rédini F; Ory B; Heymann D Cancer Lett; 2014 Mar; 344(2):291-8. PubMed ID: 24333720 [TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. Lee M; Wiedemann T; Gross C; Leinhäuser I; Roncaroli F; Braren R; Pellegata NS Clin Cancer Res; 2015 Jul; 21(14):3204-15. PubMed ID: 25838390 [TBL] [Abstract][Full Text] [Related]
20. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Schnell CR; Stauffer F; Allegrini PR; O'Reilly T; McSheehy PM; Dartois C; Stumm M; Cozens R; Littlewood-Evans A; García-Echeverría C; Maira SM Cancer Res; 2008 Aug; 68(16):6598-607. PubMed ID: 18701483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]